189 related articles for article (PubMed ID: 36845744)
21. A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.
Xu J; Liu F; Li Y; Shen L
Cell Mol Neurobiol; 2022 Apr; 42(3):709-722. PubMed ID: 32894375
[TBL] [Abstract][Full Text] [Related]
22. Establishment and Validation of a 5 m6A RNA Methylation Regulatory Gene Prognostic Model in Low-Grade Glioma.
Bai Z; Wang X; Zhang Z
Front Genet; 2022; 13():655169. PubMed ID: 35281815
[No Abstract] [Full Text] [Related]
23. Identification and Validation of an Energy Metabolism-Related lncRNA-mRNA Signature for Lower-Grade Glioma.
Zhao J; Wang L; Wei B
Biomed Res Int; 2020; 2020():3708231. PubMed ID: 32802843
[TBL] [Abstract][Full Text] [Related]
24. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
25. A novel model based on necroptosis-related genes for predicting immune status and prognosis in glioma.
Yuan YS; Jin X; Chen L; Liao JM; Zhang Y; Yu KW; Li WK; Cao SW; Huang XZ; Kang CM
Front Immunol; 2022; 13():1027794. PubMed ID: 36389690
[TBL] [Abstract][Full Text] [Related]
26. Lipid metabolism-related gene signature predicts prognosis and depicts tumor microenvironment immune landscape in gliomas.
Li J; Zhang S; Chen S; Yuan Y; Zuo M; Li T; Wang Z; Liu Y
Front Immunol; 2023; 14():1021678. PubMed ID: 36860853
[TBL] [Abstract][Full Text] [Related]
27. Identification of tryptophan metabolic gene-related subtypes, development of prognostic models, and characterization of tumor microenvironment infiltration in gliomas.
Liu Y; Xiang J; Liao Y; Peng G; Shen C
Front Mol Neurosci; 2022; 15():1037835. PubMed ID: 36407768
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Guo F; Hong J
Front Genet; 2020; 11():441. PubMed ID: 32431729
[TBL] [Abstract][Full Text] [Related]
29. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.
Tan S; Spear R; Zhao J; Sun X; Wang P
Front Genet; 2022; 13():905047. PubMed ID: 35832194
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
Wang L; Wang L; He P
Front Genet; 2022; 13():1064432. PubMed ID: 36568383
[No Abstract] [Full Text] [Related]
32. Prognostic significance and immune landscape of a fatty acid metabolism-related gene signature in colon adenocarcinoma.
Liu X; Fang X; Lu L; Liu G
Front Genet; 2022; 13():996625. PubMed ID: 36568396
[No Abstract] [Full Text] [Related]
33. Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients.
Yan Z; Gao Y; Yu J; Shen Z; Bu X
J Immunol Res; 2022; 2022():8972730. PubMed ID: 35647198
[TBL] [Abstract][Full Text] [Related]
34. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
35. Clinical and Biological Significance of a Necroptosis-Related Gene Signature in Glioma.
Zhou Z; Xu J; Huang N; Tang J; Ma P; Cheng Y
Front Oncol; 2022; 12():855434. PubMed ID: 35719998
[TBL] [Abstract][Full Text] [Related]
36. Identification and validation of a three-gene signature as a candidate prognostic biomarker for lower grade glioma.
Xiao K; Liu Q; Peng G; Su J; Qin CY; Wang XY
PeerJ; 2020; 8():e8312. PubMed ID: 31921517
[TBL] [Abstract][Full Text] [Related]
37. A Prognostic Microenvironment-Related Immune Signature
Qiu H; Li Y; Cheng S; Li J; He C; Li J
Front Oncol; 2020; 10():580263. PubMed ID: 33425732
[TBL] [Abstract][Full Text] [Related]
38. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
Xu HH; Wang HL; Xing TJ; Wang XQ
Front Immunol; 2022; 13():851622. PubMed ID: 35924232
[TBL] [Abstract][Full Text] [Related]
39. PRLHR Immune Genes Associated With Tumor Mutation Burden can be Used as Prognostic Markers in Patients With Gliomas.
Liu Y; Xiang J; Peng G; Shen C
Front Oncol; 2022; 12():620190. PubMed ID: 35800054
[TBL] [Abstract][Full Text] [Related]
40. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
